Kumar Anita J, Banco Darcy, Steinberger Elise E, Chen Joanna, Weidner RuthAnn, Makim Shital, Parsons Susan K
Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
Department of Medicine, Tufts University School of Medicine, Boston, MA, USA.
Cancer Med. 2020 May;9(9):3252-3258. doi: 10.1002/cam4.2970. Epub 2020 Mar 11.
Screening mammography has reduced breast cancer-associated mortality worldwide. Approximately 10% of patients require further diagnostic testing after an uncertain screening mammogram (Breast imaging reporting and data system [BI-RADS] = 0), and time to diagnostic resolution varies after BI-RADS = 0 screening mammogram. There is little data about factors associated with diagnostic resolution in patients of Chinese origin ("Chinese") receiving care in the US.
We performed a retrospective analysis to identify patterns of diagnostic resolution in an urban US hospital with a large population of Chinese patients. We evaluated whether location of primary care provider (PCP) impacted time to resolution among Chinese patients, hypothesizing that patients with a PCP outside of the hospital would have longer time to diagnostic resolution than those patients with a PCP within the institution.
Between 2015 and 2016, 368 patients at Tufts Medical Center (Tufts MC) had resulting BI-RADS = 0 after screening mammogram. The majority of patients (341/368, 93%) achieved diagnostic resolution with median time to resolution 27 days (Q1: 14, Q3: 40). Seven percent (27/368) never achieved resolution. Among those with diagnostic resolution, 10% of patients required >60 days to achieve resolution. Chinese origin, no previous breast cancer, subsidized insurance, and outside referring physician were associated with longer time to resolution in univariable analysis. In multivariable regression, after adjusting for age, insurance, marital status, and prior breast cancer, Chinese patients with Tufts MC PCP experienced timelier diagnostic resolution vs Chinese patients without a Tufts MC PCP (hazard ratio [HR] = 1.85, P = .02). Location of PCP did not impact time to resolution among non-Chinese patients.
We identified patterns of diagnostic resolution in an urban hospital with a large historically underserved population. We found that Chinese patients without integrated primary care within the institution are at risk for delayed diagnostic resolution. Future interventions need to target at-risk patients to prevent loss of follow-up after uncertain screening mammogram.
乳腺钼靶筛查已在全球范围内降低了乳腺癌相关死亡率。约10%的患者在乳腺钼靶筛查结果不确定(乳腺影像报告和数据系统[BI-RADS]=0)后需要进一步的诊断性检查,且BI-RADS=0的乳腺钼靶筛查后诊断明确的时间各不相同。关于在美国接受治疗的华裔患者中与诊断明确相关因素的数据很少。
我们进行了一项回顾性分析,以确定一家有大量华裔患者的美国城市医院中的诊断明确模式。我们评估了初级保健提供者(PCP)的地点是否会影响华裔患者的诊断明确时间,假设医院外的PCP患者比机构内有PCP的患者诊断明确所需时间更长。
2015年至2016年期间,塔夫茨医疗中心(Tufts MC)有368例患者在乳腺钼靶筛查后BI-RADS=0。大多数患者(341/368,93%)实现了诊断明确,诊断明确的中位时间为27天(第一四分位数:14,第三四分位数:40)。7%(27/368)的患者从未实现诊断明确。在实现诊断明确的患者中,10%的患者需要>60天才能实现诊断明确。在单变量分析中,华裔、既往无乳腺癌、有补贴保险和外部转诊医生与诊断明确时间较长相关。在多变量回归中,在调整年龄、保险、婚姻状况和既往乳腺癌后,有Tufts MC PCP的华裔患者与没有Tufts MC PCP的华裔患者相比,诊断明确更及时(风险比[HR]=1.85,P=0.02)。PCP的地点对非华裔患者的诊断明确时间没有影响。
我们确定了一家历史上服务不足人群众多的城市医院中的诊断明确模式。我们发现机构内没有综合初级保健的华裔患者有诊断延迟的风险。未来的干预措施需要针对高危患者,以防止在乳腺钼靶筛查结果不确定后失去随访。